Source: Deutsches Krebsforschungszentrum (DKFZ) / T. Schwerdt
The Deutsches Krebsforschungszentrum (German Cancer Research Center, DKFZ) has a worldwide reputation of excellence in basic and translational cancer research and is one of the leading research centers in this area, highlighted by the 2008 Nobel prize in Medicine to Prof. Harald zur Hausen as well as the 2014 Nobel prize in Chemistry for to Stefan Hell. Established in 1964 as a foundation under public law, the DKFZ has today a staff of over 3000, including more than 1000 scientists and 2000 employees providing technical and administrative support. In 2016, the total budget was 242 million € funded by the Federal German Government, the State of Baden-Württemberg and third-party funding. The DKFZ is a member of the Helmholtz Association – Germany’s largest research organization. The strategic goals of the DKFZ are to contribute towards a better understanding of fundamental processes in cancer and to develop innovative methods of cancer diagnostics and therapy. The research programme is divided into six main research areas: Cell Biology and Tumor Biology; Functional and Structural Genomics; Cancer Risk Factors and Prevention; Tumor Immunology; Imaging and Radiooncology and Infection and Cancer.
All research programs are reviewed and evaluated every five years by an international panel of experts. Co-operations with many clinics and hospitals in the area provide the opportunity to link basic and clinical research. To support “Bench to bed side” translational research, the DKFZ together with the Medical Center of the University of Heidelberg founded the first “Comprehensive Cancer Center” in Germany (National Center for Tumor Diseases, NCT), providing an exceptional environment for translational biomedical research in terms of infrastructure and expertise.
Im Neuenheimer Feld FELD 280, HEIDELBERG 69120, Germany